11 subscribers
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
المدونة الصوتية تستحق الاستماع
برعاية


1 Love Is Blind S8: Pods & Sober High Thoughts w/ Courtney Revolution & Meg 1:06:00
Breaking down the 55 new drug approvals of 2024
Manage episode 460390681 series 3386301
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these firms are bringing to the market.
In this week’s episode of “The Top Line,” we take a deep dive into the FDA’s list of drugs that were approved in 2024. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss why biotechs emerged with more approvals than large drugmakers and which new drugs figure to have the most impact for patients.
To learn more about the topics in this episode:
2024 drug approvals: Small companies loom large with several key FDA nods
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.
See omnystudio.com/listener for privacy information.
102 حلقات
Manage episode 460390681 series 3386301
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these firms are bringing to the market.
In this week’s episode of “The Top Line,” we take a deep dive into the FDA’s list of drugs that were approved in 2024. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss why biotechs emerged with more approvals than large drugmakers and which new drugs figure to have the most impact for patients.
To learn more about the topics in this episode:
2024 drug approvals: Small companies loom large with several key FDA nods
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.
See omnystudio.com/listener for privacy information.
102 حلقات
كل الحلقات
×
1 Research reveals ‘ticking DNA clock’ behind Huntington’s disease 19:28

1 What were the biggest clinical trial flops of 2024? 10:17

1 A heartwarming roundup of cardiovascular news and most-loved stories 12:05

1 Looking ahead at the most anticipated drug launches of 2025 14:07

1 What to expect from the biotech IPO market in 2025 34:06

1 Recapping the 2025 J.P. Morgan Healthcare Conference 20:47

1 Fierce's forecasts for the next year in biopharma 25:10

1 An additional treatment option with TAGRISSO® (osimertinib) (Sponsored) 14:25

1 Breaking down the 55 new drug approvals of 2024 13:03

1 Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more 39:41

1 Novo Nordisk’s chief scientific officer looks to the future of GLP-1s 32:45

1 What can we learn from 2024’s biotech IPOs? 15:06

1 Meet 2024’s fiercest women in life sciences 12:30

1 Misconduct and the future of neurodegenerative disease research 15:29

1 Dig into this year’s Fierce Biotech Graveyard, layoff numbers 11:51
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.